Estimated reading time: 4 minutes

Thank you for reading this post, Please install our onetrader.in web application for regular updates!

Suraksha Diagnostic: Can New Centres Drive the Next Phase of Growth?

Suraksha Diagnostic has started FY27 with strong operating performance, giving investors a fresh reason to track the diagnostics company. The key feature of the latest performance is not just revenue growth, but the improvement in profitability as newer centres begin contributing to the business. The company is also continuing with its expansion strategy, with management targeting a network of 100 centres by FY28.

Strong Q1 FY27 Performance

Suraksha Diagnostic reported revenue of about ₹88.7 crore in Q1 FY27, representing growth of more than 20% year-on-year. Net profit increased to around ₹13 crore, while EBITDA rose to approximately ₹31.5 crore. The EBITDA margin also improved to around 36%, indicating better operating leverage as the business scales.

The improvement in profitability is particularly important for a diagnostics company expanding its network. New centres typically require time to reach optimum utilisation. If these facilities become profitable faster than expected, the company can potentially expand without putting excessive pressure on overall margins.

Expansion Is Becoming a Key Growth Driver

Suraksha Diagnostic has been expanding beyond its established eastern India base. The company ended FY26 with 68 centres and is targeting 100 centres by FY28. The strategy is focused on building a scalable network while gradually improving the profitability of newer locations.

Also Read: Tempsens Instruments IPO: Should Investors Consider the Issue?

This creates a potentially important growth runway. As more centres mature, revenue can increase while fixed costs are spread across a larger customer base. However, the success of this strategy will depend on how quickly new centres achieve sustainable utilisation and profitability.

Why Margins Matter

Diagnostics is a competitive business, and revenue growth alone does not necessarily translate into strong shareholder returns. Suraksha’s improving EBITDA margin therefore deserves attention.

Higher volumes, operating leverage and better utilisation of the company’s network can support profitability. If the company can maintain healthy margins while continuing to add centres, earnings growth could become more consistent over the next few years.

The opposite is also possible. Rapid expansion can increase employee costs, rental expenses and other operating costs before new centres reach maturity. Investors therefore need to monitor whether profitability improves alongside expansion.

Also Read: Sky Gold & Diamonds: Strong Growth Meets Improving Margins

What Investors Should Watch

The most important metric going forward will be the performance of newly opened centres. Investors should watch how quickly these locations become profitable and whether the company can maintain its margins while expanding.

Revenue growth, patient volumes, average revenue per patient, EBITDA margins and cash generation will also provide clues about the quality of the growth. The company’s ability to reach 100 centres by FY28 without compromising returns will be an important part of the investment story.

Competition is another factor to consider. India’s organised diagnostics market continues to attract established players and regional chains, meaning Suraksha will need to maintain service quality, pricing competitiveness and network efficiency as it expands.

Conclusion

Suraksha Diagnostic’s Q1 FY27 performance shows a combination of strong revenue growth, higher profitability and improving margins. More importantly, the company appears to be demonstrating that newer centres can become productive as the network expands.

Also Read: Indian Defence Stocks in 2026: Growth Opportunity or Valuation Risk?

The next stage will be about execution. If Suraksha can continue adding centres while maintaining profitability and cash generation, the expansion strategy could support sustained earnings growth. For investors, however, the key is to track the quality and efficiency of that growth rather than focusing only on the headline expansion numbers.

This article is for educational purposes only and does not constitute investment advice.

FAQ Questions

How did Suraksha Diagnostics perform in Q1 FY27?
Suraksha Diagnostics reported strong revenue and profit growth in Q1 FY27, along with improving EBITDA margins.

What is driving Suraksha Diagnostics’ growth?
Network expansion and improving performance from newer diagnostic centres are important drivers of the company’s growth strategy.